Search

Now showing items 1-10 of 10

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

Huberman, K; Aminova, O; Thomas, S; Dolgalev, L; Van Vlierberghe, P; Racevskis, J; Sun, Z; Fernandez, H; Figueroa, ME; Gönen, M; Patel, JP; Cheng, J; van den Brink, MR; Litzow, M; Gallagher, RE; Ketterling, RP; Viale, A; Socci, ND; Heguy, A; Cherry, A; Vance, G; Higgins, RR; Levine, RL; Abdel-Wahab, O; Melnick, A; Tallman, MS; Paietta, E; Ferrando, A; Luger, S; Rowe, JM; Lazarus, HM (2012)

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated ...

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis

Diab, A; Zickl, L; Abdel-Wahab, O; Jhanwar, S; Gulam, MA; Panageas, KS; Patel, JP; Jurcic, J; Maslak, P; Paietta, E; Mangan, JK; Carroll, M; Fernandez, HF; Teruya-Feldstein, J; Luger, SM; Douer, D; Litzow, MR,; Lazarus, HM; Rowe, JM; Levine, RL; Tallman, MS (2013)

Previous small series have suggested that acute myeloid leukemia with t(8;16) is a distinct morphologic and clinical entity associated with poor prognosis. We describe 18 patients with t(8;16) AML, including their clinical, ...

How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?

Patel, JP; Levine, RL (2012)

Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults, and the majority of patients with AML die from relapsed disease. Although many studies over the past 4 decades have identified disease ...

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

Levine, RL; Bernstein, BE; Aifantis, I; Jaffe, JD; Nimer, SD; Melnick, A; Carroll, M; Abdel-Wahab, O; Park, CY; Taylor, JE; Zhao, X; Perna, F; Koche, R; Chung, YR; Patel, JP; Pandey, S; Shih, AH; Hricik, T; Gao, J; LaFave, LM; Adli, M (2012)

Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic and clinical data ...

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

Meyer, JA; Wang, J; Hogan, LE; Yang, JJ; Dandekar, S; Patel, JP; Tang, Z; Zumbo, P; Li, S; Zavadil, J; Levine, RL; Cardozo, T; Hunger, SP; Raetz, EA; Evans, WE; Morrison, DJ; Mason, CE; Carroll, WL (2013)

Relapsed childhood acute lymphoblastic leukemia (ALL) carries a poor prognosis, despite intensive retreatment, owing to intrinsic drug resistance. The biological pathways that mediate resistance are unknown. Here, we report ...

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

Levine, RL; Abdel-Wahab, O; Brennan, CW; Godley, LA; Melnick, A; Mason, CE; Gonen, M; Bhatt, PK; Socci, N; Hassimi, M; Heguy, A; Viale, A; Li, J; Mollica, L; Hamilou, Z; Provost, S; Vasanthakumar, A; Busque, L; Patel, JP; Figueroa, ME (2012)

Abstract Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated ...

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

Oyer, JA; Huang, X; Zheng, Y; Shim, J; Ezponda, T; Carpenter, Z; Allegretta, M; Okot-Kotber, CI; Patel, JP; Melnick, A; Levine, RL; Mackerell, AD; Kelleher, NL; Licht, JD; Popovic, R (2013)

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

DiNardo, CD; Propert, KJ; Loren, AW; Paietta, E; Sun, Z; Levine, RL; Straley, KS; Yen, K; Patel, JP; Agresta, S; Abdel-Wahab, O; Perl, AE; Litzow, MR; Rowe, JM; Lazarus, HM; Fernandez, HF; Margolis, DJ; Tallman, MS; Luger, SM; Carroll, M (2013)

Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the metabolite 2-hydroxyglutarate (2HG), but the clinical utility of 2HG has not been established. We studied whether 2HG measurements in acute myeloid ...

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Gönen, M; Sun, Z; Figueroa, ME; Patel, JP; Abdel-Wahab, O; Racevskis, J; Ketterling, RP; Fernandez, H; Rowe, JM; Tallman, MS; Melnick, A; Levine, RL; Paietta, E (2012)

We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified ...

The role of mutations in epigenetic regulators in myeloid malignancies

Shih, AH; Abdel-Wahab, O; Patel, JP; Levine, RL (2012)

The role of mutations in epigenetic regulators in myeloid malignancies. Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative ...